Parkinson’s Disease: Global Drug Forecast and Market Analysis to 2026

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$10995
Buy Report View Sample

Published: May 31, 2018 Report Code: GDHC167PIDR-ST

Select Item

Parkinson’s disease (PD) is a chronic and progressive disease, considered an idiopathic form, and accounts for roughly 80% of the cases of Parkinsonism—neurological disorders that lead to movement problems. While the exact cause of Parkinson’s disease is unknown, it may include a number of factors such as aging, environmental factors/exposures, and genetic predispositions.
Current treatments centre on the management of dopamine levels in the brain, with levodopa-based therapies remaining the standard of care in the Parkinson’s market for the past half century. These therapies provide the best relief of symptoms at a low annual cost of therapy (ACOT), with Sinemet (carbidopa/levodopa) and Madopar (benserazide/levodopa) being the two most popular branded drugs.
GlobalData estimates that drug sales for PD in 2016 were approximately $3.1B across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to $8.8B at a CAGR of 11.1%. This growth will be driven by the launch of thirteen late-stage pipeline products. The two highest selling drugs are expected to be Roche/Prothena’s PRX-002and Acorda’s CVT-301, which both address some of the unmet needs in the market.
Key Questions Answered
What are the key PD treatments in 2016?
When will the late stage pipeline products launch, and how will it affect drug sales and the overall PD market in the 7MM?
Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Scope

Overview of PD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized PD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (early and advanced) forecast from 2016 to 2026.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD therapeutics market

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PD therapy. The most promising candidates in Phase III development are profiled.

Analysis of the current and future market competition in the global PD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global PD therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PD therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Teva
Roche
Prothena
Acorda Therapeutics
Voyager Therapeutics
Impax Pharmaceuticals
UCB
AbbVie
Novartis
Orion Pharmaceuticals
Intec Pharma
NeuroDerm
Adamas Therapeutics
Acadia
Sunovion
Roche
MSD
GSK
Britannia Pharmaceuticals
Novo Nordisk
Integrative Research Laboratories (IRLAB)
Lundbeck
US WorldMeds
Zambon
Eisai
Meiji Seika
Addex Therapeutics
Sanofi
Neurocrine Biosciences
Ono Pharmaceuticals
Otsuka Pharmaceutical
Takeda
Bial
Newron
Kyowa Hakko Kirin
Genzyme

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Parkinson’s Disease: Executive Summary

2.1 Parkinson’s Market Forecast to Reach $8.8B by 2026

2.2 New Players Expected to Establish Themselves in the Forecast Period as Late-Stage Pipeline Assets Launched

2.3 Disease-Modifying Agents and Late-Stage Complications the Largest Unmet Needs in the PD Market

2.4 Treatments for Late-Stage Complications, Including Dyskinesia and Psychosis, Provide Companies with European and Japanese Opportunity

2.5 Biologics and Reformulations Expected to Drive Growth Pipeline

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology

4.1.1 Overview

4.1.2 Aging

4.1.3 Environmental Factors

4.1.4 Genetic Factors

4.2 Pathophysiology

4.2.1 Overview

4.2.2 Mechanisms of Cell Death

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.3.1 US

5.3.2 5EU

5.3.3 Japan

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Sources Not Used

5.4.3 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for PD (2016–2026)

5.5.1 Diagnosed Prevalent Cases of PD

5.5.2 Age-Specific Diagnosed Prevalent Cases of PD

5.5.3 Sex-Specific Diagnosed Prevalent Cases of PD

5.5.4 Diagnosed Prevalent Cases of PD by Clinical Staging

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.2 US

6.3 5EU

6.4 Japan

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Treatment of Motor Complications – Dyskinesia and OFF Episodes

8.3 Treatment of Non-motor Complications and Dementia

8.4 Neuroprotective/Disease-Modifying Agents

8.5 Improved Drug Formulations

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 AbbVie

10.4 Roche

10.5 Orion Pharma

10.6 Impax Pharmaceuticals

10.7 Acorda Therapeutics

10.8 Adamas Pharmaceuticals

10.9 UCB

10.10 Kyowa Hakko Kirin

10.11 Other Players

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – KOLs [and Payers] Interviewed for This Report

12.4.1 KOLs

12.4.2 Payers

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: Parkinson’s Disease: Key Metrics in the 7MM

Table 2: Risk Factors and Comorbidities for PD

Table 3: 7MM, Diagnosed Prevalent Cases of PD By Clinical Staging, Both Sexes, Ages ≥18 Years, N, 2016

Table 4: Treatment Guidelines for PD

Table 5: Country Profile – US

Table 6: Country Profile – 5EU

Table 7: Country Profile – Japan

Table 8: Leading Treatments for Parkinson’s Disease, 2016

Table 9: Comparison of Therapeutic Classes in Development for Parkinson’s Disease, 2016–2026

Table 10: AbbVie’s Disease Portfolio Assessment, 2018

Table 11: Roche’s Disease Portfolio Assessment, 2018

Table 12: Orion Pharma’s Disease Portfolio Assessment, 2018

Table 13: Impax Pharmaceuticals’ Disease Portfolio Assessment, 2018

Table 14: Acorda Therapeutics’ Disease Portfolio Assessment, 2018

Table 15: Adamas Pharmaceuticals’ Disease Portfolio Assessment, 2018

Table 16: UCB’s Disease Portfolio Assessment, 2018

Table 17: Kyowa Hakko Kirin’s Disease Portfolio Assessment, 2018

Table 18: Parkinson’s Disease Market – Global Drivers and Barriers, 2016–2026

Table 19: Key Events Impacting Sales for Parkinson’s Disease in the US, 2016–2026

Table 20: Parkinson’s Disease Market – Drivers and Barriers in the US, 2016–2026

Table 21: Key Events Impacting Sales for Parkinson’s Disease in the 5EU, 2016–2026

Table 22: Parkinson’s Disease Market – Drivers and Barriers in the 5EU, 2016–2026

Table 23: Key Events Impacting Sales for Parkinson’s Disease in Japan, 2016–2026

Table 24: Parkinson’s Disease Market – Global Drivers and Barriers in Japan, 2016–2026

Table 25: Key Projected Launch Dates for Parkinson’s disease

Table 26: Key Historical and Projected Patent Expiry Dates for Parkinson’s Disease

Table 27: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for Parkinson’s Disease in 2016 and 2026

Figure 2: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period

Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of PD, Ages ≥18 Years, 2016

Figure 5: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of PD, 2016–2026

Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of PD Clinical Staging, 2016–2026

Figure 7: Diagnosed Prevalent Cases of PD, 7MM, Both Sexes, ≥18 Years, N, 2016

Figure 8: 7MM, Age-Specific Diagnosed Prevalent Cases of PD, Both Sexes, Ages ≥18 Years, N, 2016

Figure 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of PD, Both Sexes, Ages ≥18 Years, N, 2016

Figure 10: Treatment Algorithm for Parkinson’s Patients

Figure 11: Unmet Needs and Opportunities in Parkinson’s Disease

Figure 12: Pharmacokinetics of Levodopa

Figure 13: Overview of the Development Pipeline in Parkinson’s Disease

Figure 14: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for PD in the 7MM During the Forecast Period

Figure 15: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period

Figure 16: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period

Figure 17: Global (7MM) Sales Forecast by Country for Parkinson’s Disease in 2016 and 2026

Figure 18: Sales Forecast by Class for Parkinson’s Disease in the US in 2016 and 2026

Figure 19: Country Breakdown for Parkinson’s Disease Sales in the 5EU in 2016 and 2026

Figure 20: Sales Forecast by Class for Parkinson’s Disease in Japan in 2016 and 2026

Frequently asked questions

Parkinson’s Disease: Global Drug Forecast and Market Analysis to 2026 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

Most Popular
$21,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Parkinson’s Disease: Global Drug Forecast and Market Analysis to 2026 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Central Nervous System reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Parkinson’s Disease: Global Drug Forecast and Market Analysis to 2026 in real time.

  • Access a live Parkinson’s Disease: Global Drug Forecast and Market Analysis to 2026 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more